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Despite control efforts, Mycobacterium bovis incidence 
among cattle remains high in parts of England, Wales, 
and Northern Ireland, attracting political and public health 
interest in potential spread from animals to humans. To 
determine incidence among humans and to identify as-
sociated factors, we conducted a retrospective cohort 
analysis of human M. bovis cases in England, Wales, 
and Northern Ireland during 2002–2014. We identified 
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357 cases and observed increased annual case numbers 
(from 17 to 35) and rates. Most patients were >65 years 
of age and born in the United Kingdom. The median age 
of UK-born patients decreased over time. For 74% of pa-
tients, exposure to risk factors accounting for M. bovis 
acquisition, most frequently consumption of unpasteur-
ized milk, was known. Despite the small increase in case 
numbers and reduction in patient age, M. bovis infec-
tion of humans in England, Wales, and Northern Ireland 
remains rare. 
After the 1960s, the number of human cases of tubercu-losis (TB) caused by Mycobacterium bovis decreased 
significantly in England, Wales, and Northern Ireland, co-
inciding with widespread implementation of milk product 
pasteurization and national bovine TB control programs 
(1–3). During the past 2 decades in these 3 countries, an av-
erage of 30 cases of M. bovis in humans occurred annually; 
numbers decreased in the early 2000s before again increas-
ing (4–6). During the same period, incidence of M. bovis in 
cattle herds in parts of England, Wales, and Northern Ire-
land increased substantially but has now plateaued (4,7–9).
M. bovis control (2,7,10,11) attracts political, pub-
lic health, and media interest because of potential spread 
from animals to humans, effects on animal health and trade 
(1), and the role of wildlife in the transmission cycle (12). 
Highly visible interventions, including wildlife manage-
ment to prevent transmission to livestock, are used to at-
tempt to control M. bovis spread (6,9,10), thereby protect-
ing human health.
Compared with other countries in western Europe, the 
rate of TB among humans in the United Kingdom is high: 
9.6 cases/100,000 population (6,240 cases) in 2015 (13). 
Most TB cases occurred in those born abroad, who prob-
ably acquired infection before entering the United King-
dom. Although only 1.1% (42 cases) of culture-confirmed 
TB cases were caused by M. bovis (6), it remains a public 
health priority.
The drivers of the epidemiology of M. tuberculosis 
are well described (13–15). However, there is compar-
atively less information on the sources of M. bovis in 
humans, other than the recognized risks of unpasteur-
ized milk consumption and close contact with infected 
cattle (1,3). We provide an update on the demographic 
characteristics of humans with M. bovis disease in Eng-
land, Wales, and Northern Ireland (16). To address the 
gap in knowledge regarding lesser known sources of 
acquisition, we describe the demographic and clinical 
characteristics of humans with TB caused by M. bovis 
compared with M. tuberculosis. In addition, we describe 
potential human exposures that may indicate M. bovis 
acquisition and include a genotyping comparison of the 
causative organisms.
Materials and Methods
Study Population and Definitions
Our retrospective cohort study included all human M. bo-
vis patients in the descriptive analysis. To describe demo-
graphic and clinical characteristics associated with M. bo-
vis disease, we compared all M. bovis notified patients with 
all M. tuberculosis notified patients. Potential exposures to 
risk factors associated with M. bovis acquisition were col-
lected through a questionnaire and limited to M. bovis cases 
identified during 2006–2014, when the questionnaire return 
rate was high (>80%).
An M. bovis case was defined as a culture-confirmed 
human case of TB speciated as M. bovis isolated during 
2002–2014. A notified M. bovis case was an M. bovis case 
clinically notified to the Enhanced TB Surveillance system 
(ETS); a nonnotified M. bovis case was an M. bovis not 
reported clinically to ETS. An M. tuberculosis notified case 
was defined as a culture-confirmed human case of TB spe-
ciated as M. tuberculosis isolated during 2002–2014 and 
clinically notified to ETS. 
Data Collection
Results from culture-positive laboratory isolates were sent 
from Mycobacterium reference laboratories in England, 
Wales, and Northern Ireland to Public Health England. 
These results were matched with notified TB cases from 
ETS, used for statutory notification of TB, by use of a prob-
abilistic matching method (17).
Data on demographics (age, sex, ethnicity, country of 
birth, time since UK entry, address, and occupation); clinical 
factors (site of disease and previous diagnosis); and social 
risk factors (current or past imprisonment, homelessness, 
drug and alcohol misuse) were obtained from ETS notifica-
tions. For nonnotified M. bovis cases, the only patient demo-
graphic information available was age, sex, and address; the 
disease site was inferred from specimen site. For analysis, 
we used the age groups 0–14, 15–44, 45–64, and >65 years 
and the ethnic groups white, black African, Indian subconti-
nent (Indian, Pakistani, and Bangladeshi grouped together), 
and other. After assignment to a geographic area of residence 
based on address, the place of residence was classified as 
rural or urban by using 2011 census classifications (18).
After identification of an M. bovis case (based on phe-
notypic, PCR, and genotypic methods [19,20]), a question-
naire (online Technical Appendix, https://wwwnc.cdc.gov/
EID/article/23/3/16-1408-Techapp1.pdf) (21) was issued to 
collect information on potential recognized current or past 
M. bovis exposures. These exposures were contact with a 
human TB patient, travel (for >2 weeks) to or residence 
in a country with high TB incidence (defined as having 
an estimated rate of >40 cases/100,000 population during 
2002–2014), consumption of unpasteurized milk product, 
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occupational contact with animals, physical contact with 
wild (nondomestic) animals, and physical contact with any 
animal with TB (including pets).
M. bovis Trend Analysis
We calculated incidence rates per 100,000 population by 
using mid-year population estimates produced by the UK 
Office for National Statistics (22). We used Poisson regres-
sion to calculate the incidence rate ratio to assess the trend 
in M. bovis incidence over time. We used a nonparametric 
test for trend across ordered groups to assess the age trend 
of M. bovis patients and the χ2 test for trend to assess the 
proportion of M. bovis among culture-confirmed TB cases.
Factors Associated with M. bovis Disease and  
M. tuberculosis Disease
Demographic and clinical characteristics for M. bovis noti-
fied patients were compared with those of M. tuberculosis 
notified patients by using univariable and multivariable lo-
gistic regression to calculate odds ratios to identify factors 
associated with M. bovis disease. A forward stepwise mul-
tivariable logistic regression model was used, including sex 
and all variables with a p value <0.2 in univariable analysis; 
likelihood ratios were assessed after each stepwise addition 
to the model. In addition, we conducted a stratified analysis 
based on place of birth (UK-born/non–UK-born). A p value 
of <0.05 was considered statistically significant. We tested 
interactions between biologically and statistically plausible 
variables in the model by using likelihood ratios. All analy-
ses were conducted by using Stata 13.1 (StataCorp LLC, 
College Station, TX, USA).
Exposures to Risk Factors Associated with  
M. bovis Disease
To identify frequent exposure to risk factors among the co-
hort, we used case exposure history, as collected through 
the questionnaire (online Technical Appendix), for descrip-
tive analysis. In addition to obtaining questionnaire infor-
mation about contact with another human TB patient, for 
culture-positive isolates identified during 2010–2014, we 
also obtained 24-loci mycobacterial interspersed repetitive 
unit–variable tandem repeat (MIRU-VNTR) strain typing 
results (20) from Mycobacterium reference laboratories. 
This information enabled us to identify strain type clusters, 
defined as >2 human TB cases with indistinguishable MI-
RU-VNTR profiles (or with an indistinguishable profiles 
but with 1 case only typed to 23 loci), Clustered cases were 
further investigated to identify possible epidemiologic 
links, the identification of which suggest recent human-to-
human transmission (23).
Results
Demographics of M. bovis Patients
For 2002–2014, we identified 357 culture-confirmed cases 
of M. bovis disease in humans. During this time, the pro-
portion of all culture-confirmed TB cases speciated as M. 
bovis increased from 0.4% to 0.9% (p<0.001). Annual case 
numbers ranged from 17 in 2002 to 35 in 2014, and the inci-
dence rate fluctuated between 0.03 and 0.06 cases/100,000 
population (Figure 1); the incidence rate ratio per year was 
1.04 (95% CI 1.01–1.07). Overall, 92.2% (329/357) of M. 
bovis cases were notified to ETS; since 2011, all identified 
cases have been notified.
Among 297 M. bovis patients for whom place of birth 
was recorded, 214 (72.1%) were born in the United King-
dom. The most frequent countries of birth for the others were 
Nigeria (18 patients), Morocco (9 patients), and India (8 pa-
tients). The age distribution differed significantly between 
those born and not born in the United Kingdom (p<0.001) 
(Table 1). The median age of UK-born patients fluctu-
ated over time, from 71 years (interquartile range 60–76) 
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Figure 1. Annual number 
and incidence rate (no. 
cases/100,000 population) 
of notified Mycobacterium 
bovis cases by patient place 
of birth, England, Wales, and 
Northern Ireland, 2002–2014. 
Unknown place of birth includes 
notifications with an unknown 
place of birth and cases that 
have not been notified.
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in 2002 to 53 years (interquartile range 35–79) in 2014 (p = 
0.099), as did the proportion of cases by age group (Figure 
2). Only 6 M. bovis cases in patients <15 years of age were 
reported (all 11–14 years of age).
For all 3 countries, the highest proportion of M. bo-
vis patients resided in London, England (18.5%; 66/357), 
followed by the South West (15.4%; 55) and West Mid-
lands regions of England (13.2%; 47) (Figure 3, panel A). 
However, the incidence rate was highest in Northern Ireland 
(0.11 cases/100,000 population), followed by the South 
West (0.08/100,000) and West Midlands (0.07/100,000) re-
gions. The highest proportion (71.9%; 41/57) of M. bovis 
patients not born in the United Kingdom lived in London. In 
comparison, 85.1% (40/47) and 82.1% (32/39) of patients 
from the South West and West Midlands, respectively, were 
born in the United Kingdom.
Comparison between Notified M. bovis and  
M. tuberculosis Patients
Univariable analysis showed that, when compared with M. 
tuberculosis notified patients, M. bovis notified patients 
were more likely to be >45 years of age, born in the United 
Kingdom, of an ethnic group other than that of the Indian 
subcontinent, live in a rural area, and work in agricultural 
or animal-related occupations. M. bovis patients were less 
likely than M. tuberculosis patients to have pulmonary dis-
ease. Multivariable analysis showed that the same factors, 
other than age, were independently associated with M. bo-
vis; only those >65 years of age were more likely to have 
M. bovis disease. The strongest risk factor for M. bovis 
disease was working in an agricultural or animal-related 
occupation (adjusted odds ratio 29.5, 95% CI 16.9–51.6; 
Table 2). The model showed no interactions between ex-
planatory variables. Analysis stratifying by place of birth 
(UK-born vs. non–UK-born) indicated that the same vari-
ables were significant.
M. bovis Patient Exposure to Risk Factors
Of the 272 M. bovis patients identified during 2006–2014, 
exposure questionnaires were completed for 241 (88.6%). 
Of these, 179 (74.3%) reported exposure to at least 1 risk 
factor for M. bovis acquisition; 78 (43.6%) reported 1 ex-
posure, 57 (31.8%) 2 exposures, 28 (15.6%) 3 exposures, 
and 16 (8.9%) 4 exposures. For 6 patients, no exposure was 
known; for the remaining 56 patients, data were missing for 
>1 risk factor and the patients could not be classified as not 
having been exposed to a risk factor.
The most frequently reported exposure was con-
sumption of unpasteurized milk products (65.7%, 
109/166; Table 3); proportions reporting this factor were 
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Table 1. Characteristics of patients with Mycobacterium bovis disease, England, Wales, and Northern Ireland, 2002–2014* 
Characteristic† 
All patients, no. (%), 
n = 357‡ 
UK-born patients, no. (%), 
n = 214§ 
Non–UK-born patients, no. (%),  
n = 83¶ 
Age group, y    
 0–14 6 (1.7) 4 (1.9) 2 (2.4) 
 15–44 106 (29.7) 39 (18.2) 54 (65.1) 
 45–64 70 (19.6) 45 (21.0) 12 (14.5) 
 >65 175 (49.0) 126 (58.9) 15 (18.1) 
Male sex 196 (55.1) 130 (60.8) 37 (44.6) 
Ethnicity    
 White 230 (73.0) 199 (93.9) 15 (18.5) 
 Black African 37 (11.8) 2 (0.9) 35 (43.2) 
 Indian subcontinent 16 (5.1) 3 (1.4) 9 (11.1) 
 Other 32 (10.2) 8 (3.8) 22 (27.2) 
Time since entered United Kingdom, y    
 <2 NA NA 10 (14.7) 
 2–5 NA NA 17 (25.0) 
 6–10 NA NA 20 (29.4) 
 >10 NA NA 21 (30.9) 
Place of residence    
 Rural 86 (24.9) 62 (29.0) 9 (10.8) 
 Urban 259 (75.1) 152 (71.0) 74 (89.2) 
Pulmonary TB#    
 Yes 199 (56.9) 131 (61.5) 38 (45.8) 
 No 151 (42.3) 82 (38.5) 45 (54.2) 
>1 social risk factor** 12 (7.9) 6 (5.9) 5 (11.1) 
Previous TB diagnosis 17 (6.1) 13 (6.7) 5 (5.4) 
*IQR, interquartile range; NA, not applicable; TB, tuberculosis.  
†Sex, age, and site of disease reported for all cases (excluding breakdowns by birth in or not in the United Kingdom); all other characteristics reported 
only for notified cases. 
‡Median age (IQR) 58 (36–77) y. 
§Median age (IQR) 70 (52–79) y. 
¶Median age (IQR) 35 (28–58) y. 
#Pulmonary TB with or without extrapulmonary TB, those recorded as “no” had exclusively extrapulmonary TB. 
**Data only available from 2010 on. 
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similar among those born in the United Kingdom and 
those born elsewhere. Among those for whom the most 
recent consumption of unpasteurized milk product was 
known, most (85.9%, 55/64) had consumed the product 
>5 years before TB diagnosis; 42.2% (27/64) were >50 
years of age before diagnosis. No change in the age dis-
tribution of patients consuming unpasteurized milk was 
identified over time; most (56.0%, 61/109) were >65 
years of age.
Contact with a human TB patient was reported by 
18.2% (33/181), but for most, recorded information was in-
sufficient to identify the contact, particularly if the contact 
was not recent. Where known, 80.8% (21/26) of contacts 
occurred >5 years before TB diagnosis. From 24-loci MI-
RU-VNTR strain typing data available during 2010–2014, 
a total of 48.7% (57/117) of patients (of which 46 were 
born in the United Kingdom and 9 were not) were in 15 M. 
bovis strain type clusters. One cluster contained exclusively 
patients not born in the United Kingdom and 7 exclusively 
born in the United Kingdom; 2 of the latter clusters con-
tained the only epidemiologically linked human patients, 
each with a pair of household contacts.
Recent acquisition of infection cannot be directly 
measured, but the rate of M. bovis disease among chil-
dren, along with their exposures, can provide an indirect 
indicator of recent acquisition. Exposure information was 
available for 5/6 M. bovis patients <15 years of age and 
suggested potential overseas acquisition; 5 had traveled to 
a country where TB incidence was high, 1 of whom had 
consumed unpasteurized milk while abroad. For 1 child not 
born in the United Kingdom, a questionnaire response was 
not obtained.
Overall, among those for whom location of exposure 
was known, 59.1% (97/164) of patients were exposed to 
>1 risk factor in the United Kingdom (Table 3). Among 
those not born in the United Kingdom, 18.0% (9/50) were 
known to have been exposed to a risk factor while in the 
United Kingdom, but 4 of the 9 also were exposed outside 
the United Kingdom.
Discussion
Our findings confirm that M. bovis disease remains rare 
among humans in England, Wales, and Northern Ireland. 
Over the study period, the annual rate of M. bovis disease 
and the proportion of culture-confirmed TB cases with M. 
bovis identified as the cause displayed a small but statis-
tically significant increase; annual case numbers for the 
past 10 years were similar to those for the early 1990s (4). 
Although speciation has improved from the use of strain 
typing results (19,20), this improvement is unlikely to ac-
count for all of the increase identified. Although the pre-
vious study by Jalava et al. (4) and our study overlap by 
2 years, our results benefit from improved matching (17) 
between case notification and culture results from 2002 on, 
thereby providing improved accuracy for reporting annual 
case numbers.
We identified, unlike previous studies (4,5), that al-
though the number of M. bovis patients not born in the 
United Kingdom remained low and fluctuated over time, 
the annual number of cases in this group increased slightly 
over time. Our finding may be confounded by better re-
cording of place of birth but is not unexpected given the 
increase during this period in the overall number of TB pa-
tients not born in the United Kingdom (13). Similar to pre-
vious findings (5), our findings indicate that most M. bovis 
patients not born in the United Kingdom lived in urban ar-
eas, specifically London. These patients originated mostly 
from low-income countries where TB incidence is high and 
therefore are at higher risk for human-to-human transmis-
sion and animal-to-human transmission because of limited 
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Figure 2. Annual number of 
notified UK-born Mycobacterium 
bovis cases, by patient age 
group, England, Wales, and 
Northern Ireland, 2002–2014.
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detection of M. bovis in animals and less frequent milk 
pasteurization (24). Thus, infection was probably acquired 
before arrival in the United Kingdom and less likely to be 
related to exposure to risk factors while in the United King-
dom. Unfortunately, speciation is not routinely conducted 
in many high TB burden, low-income countries (16), so it 
is difficult to identify in which countries incidence of M. 
bovis is high and whether the trends in country of birth for 
M. bovis patients not born in the United Kingdom reflect 
the global incidence of the disease (24,25).
We identified a decrease over time in the proportion 
of UK-born patients >65 years of age and a decrease in the 
median age, although neither was statistically significant. 
Previously, most cases in UK-born patients were the result 
of reactivation of infection acquired before the large rollout 
of pasteurization (by the 1960s) (4), when M. bovis inci-
dence was higher. Given the length of time that widespread 
pasteurization has been in place, progressively fewer cases 
among the older population are expected as the cohort ex-
posed before pasteurization decreases. It was unexpected 
that, despite this decrease, the number of M. bovis cases 
occurring in the UK-born population did not reduce over 
the study period. Instead, the number and proportion of 
younger UK-born patients increased slightly. Numbers re-
main small, and it is not possible to yet detect any change in 
exposures; however, in recent years, the media have report-
ed increased public demand for unpasteurized milk, which, 
if contaminated, could result in more human infections.
No data are available to quantify unpasteurized milk 
production or consumption within England, Wales, and 
Northern Ireland. However, results from a 2012 survey 
of adult consumer attitudes about unpasteurized milk 
(26) showed that 33% of respondents had consumed un-
pasteurized milk but only 3% currently consumed un-
pasteurized milk. Although the proportion who had ever 
consumed unpasteurized milk was highest among older 
age groups (18–24 years, 31%; 25–44 years, 28%; 45–64 
years, 38%; >65 years, 40%), the proportion of current 
consumers was higher among younger age groups (18–
24 years, 7%; 25–44 years, 4%; 45–64, 1%; >65, 1%). It 
is possible that increased consumption of unpasteurized 
milk, as reported by the media, is contributing to the small 
increase in M. bovis cases and may contribute to a change 
in demographics of patients over time. Although we do 
not have evidence to confirm, this hypothesis could be 
explored further through a formal observation study. The 
time between unpasteurized milk consumption and onset 
of TB disease among the M. bovis patients in our cohort 
emphasizes that the effects of current unpasteurized milk 
consumption may not be observed for many years.
The results of combining routine 24-loci MIRU-VN-
TR typing of M. bovis from humans with epidemiologic 
data provide evidence of only occasional human-to-hu-
man M. bovis transmission; despite extensive follow-up of 
the 57 clustered cases, only 2 instances of 2 cases being 
epidemiologically linked were found. Only 1 prior occur-
rence of MIRU-VNTR–confirmed (using 15-loci typing) 
human-to-human transmission of M. bovis in the United 
Kingdom has been documented (5,27); it occurred before 
the rollout of routine prospective 24-loci MIRU-VNTR 
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Figure 3. Cases of Mycobacterium bovis disease in England, Wales, and Northern Ireland, 2002–2014. A) Density of human cases. B) 
Density of cattle herds with TB outbreaks. This material is based on Crown Copyright and is reproduced with the permission of Land & 
Property Services under delegated authority from the Controller of Her Majesty’s Stationery Office.
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typing. There are also few examples of human-to-human 
M. bovis transmission in countries other than those includ-
ed in this study (28,29), suggesting that such transmission 
is rarely identified. Overall, the proportion of clustering 
among M. bovis cases (49%) was slightly lower than that 
of the overall proportion among all TB cases (56%) ob-
served in England (13).
This analysis also presents findings consistent with 
those previously reported (4). Although the proportion of 
cases among the older UK-born population seems to be 
decreasing, over the study period this group accounted for 
most cases. Our comparative analysis confirmed that the 
demographic profile of M. bovis patients differs from that 
of M. tuberculosis patients. The consumption of unpasteur-
ized milk remained the most frequently reported exposure, 
and M. bovis patients were more likely than M. tuberculosis 
patients to work or have worked in agricultural and ani-
mal-related occupations. These findings are reassuring and 
show that M. bovis disease is still largely limited to those 
with recognized risk factors for infection. Few incidents in-
volving animal-to-human transmission on farms (1,30,31) 
and a single incident of M. bovis transmission from a pet 
to its owners 32,33) have occurred during the study period. 
Most animal-to-human transmission remains sporadic, and 
implementation of additional specific interventions beyond 
those currently in place (1,2) would be difficult.
A high proportion of UK-born patients lived in rural 
areas, especially across the South West and Midlands of 
England, where M. bovis incidence among cattle is high 
(Figure 3, panel B). Most of these patients reported con-
sumption of unpasteurized milk or contact with animals. 
However, human patients without such exposures and who 
reside in these areas where M. bovis cattle incidence is high 
should continue to be monitored and thoroughly investi-
gated to ensure that lesser known exposures are not missed.
Similar to our study, a study in the Netherlands identi-
fied that the highest proportion of M. bovis cases occurred 
in the older native population (50%), followed by the 
foreign-born population (40%) (34). In comparison with 
our study, studies from the United States found that be-
ing foreign born (in particular, being of Hispanic ethnicity) 
and younger were independently associated with M. bovis 
when compared with M. tuberculosis (35,36). The differ-
ence in demographic characteristics of M. bovis patients 
in the United States and in England, Wales, and North-
ern Ireland may be explained by the fact that M. bovis in 
cattle or wildlife is not frequently reported in the United 
States (37,38) but is more common in neighboring Mexico 
(39,40). Thus, the epidemiology of human M. bovis in Eng-
land, Wales, and Northern Ireland continues to be driven 
by the past and, to some extent, present prevalence of dis-
ease in cattle. Given advances in molecular techniques, 
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Table 2. Demographics and risk factors for patients with Mycobacterium tuberculosis and M. bovis disease, England, Wales, and 
Northern Ireland, 2002–2014* 
Characteristic 
M. bovis patients, 
no. (%), n = 329 
M. tuberculosis patients, 
no. (%), n = 58,540 
Univariable analysis 
 
Multivariable analysis 
OR (95% CI) p value OR (95% CI) p value 
Age group, y        
 0–14 6 (1.8) 1,200 (2.1) 1.9 (0.8–4.3) <0.001  1.5 (0.6–3.6) <0.001 
 15–44 102 (31.0) 38,558 (65.9) Referent   Referent  
 45–64 61 (18.5) 10,953 (18.7) 2.1 (1.5–2.9)   1.3 (0.9–2.0)  
 >65 160 (48.6) 7,826 (13.4) 7.7 (6.0–9.9)   3.6 (2.6–5.2)  
Sex        
 M 179 (54.4) 33,715 (57.7) 0.9 (0.7–1.1) 0.229  0.9 (0.7–1.1) 0.287 
 F 150 (45.6) 24,721 (42.3) Referent   Referent 
 
UK-born        
 Yes 214 (72.1) 13,576 (24.7) 7.9 (6.1–10.1) <0.001  2.6 (1.7–4.1) <0.001 
 No 83 (27.9) 71,361 (75.3) Referent   Referent  
Ethnicity        
 White 230 (73) 11,968 (21.1) 28.0 (16.8–46.4) <0.001  14.6 (7.2–26.9) <0.001 
 Black African 37 (11.8) 12,501 (22.1) 4.3 (2.4–7.7) 
 
 7.4 (3.7–14.9) 
 
 Indian subcontinent† 16 (5.1) 23,285 (41.1) Referent   Referent  
 Other 32 (10.2) 8,905 (15.7) 5.2 (2.9–9.5)   7.3 (3.6–14.8)  
Occupation        
 Agricultural/animal 
contact work 
20 (7.9) 116 (0.3) 32.4 (19.8–53.0) <0.001  29.5 (16.9–51.6) <0.001 
 Other 232 (92.1) 43,698 (99.7) Referent   Referent  
Site of disease        
 Pulmonary 193 (58.8) 37,580 (64.2) 0.8 (0.6–1.0) 0.048  0.4 (0.3–0.5) <0.001 
 Extrapulmonary only 135 (41.2) 20,938 (35.8) Referent   Referent  
Place of residence        
 Rural 81 (24.6) 1,944 (3.3) 9.5 (7.3–12.2) <0.001  2.8 (2.0–3.9) <0.001 
 Urban 248 (75.4) 56,380 (96.7) Referent   Referent  
*Interactions between 1) place of birth (UK-born/non–UK-born) and all of the other variables (age, sex, ethnicity, occupation, site of disease, place of 
residence [rural/urban]) and 2) age and site of disease or place of residence (rural/urban) were tested. No significant interactions existed in the model. 
OR, odds ratio. 
†Indian, Bangladeshi, and Pakistani ethnic groups. 
 
SYNOPSIS
improved understanding of animal-to-human transmission 
will require linking the genotyping results from animals 
with M. bovis infection in England, Wales, and Northern 
Ireland with data from humans.
Globally, zoonotic TB should be tackled, and the 
needs of those affected by M. bovis disease, namely those 
in animal-related occupations and those consuming un-
pasteurized milk from infected animals, should be ad-
dressed. The implementation of methods to identify M. 
bovis where culture is not possible have been highlighted 
as essential (16,41,42). Although findings from England, 
Wales, and Northern Ireland cannot be extrapolated even 
to other high-income countries, much less to high TB 
burden, low-income countries, our study does illustrate 
the value of monitoring M. bovis disease and the data re-
quired to do so.
Our study does have some limitations. The exposure 
questionnaires return rate was 89%, and some responses 
were missing, which could lead to some error in the esti-
mation of exposures; in addition, nonresponders were more 
likely to be urban dwellers. Our comparison of M. bovis 
and M. tuberculosis patients was limited because expo-
sure questionnaire information was only collected for M. 
bovis patients; therefore, animal-related exposures, travel 
to countries with high TB incidence, and contact with hu-
man TB patients could not be included in the analysis. In 
addition, patients not born in the United Kingdom, most 
of whom belong to Indian subcontinent ethnic groups, 
are more likely missed in analysis because a higher pro-
portion have exclusively extrapulmonary disease (43), for 
which culture confirmation is lower. Approximately 60% 
of TB cases in England, Wales, and Northern Ireland are 
culture confirmed; therefore, the estimated M. bovis inci-
dence presented in this article is probably an underestimate. 
The proportion of TB cases culture confirmed over time 
has remained relatively stable (44), so underascertainment 
should not affect changes in the number or proportion of 
TB cases caused by M. bovis.
In conclusion, we found that M. bovis disease continues 
to account for a small number and low proportion of total 
TB cases in England, Wales, and Northern Ireland. The pro-
portion of culture-confirmed TB cases caused by M. bovis 
has increased slightly, and the age of UK-born patients has 
decreased. The reasons are not fully understood, and trends 
should continue to be monitored. For most patients, expo-
sure to risk factors for M. bovis acquisition (e.g., unpasteur-
ized milk consumption, farm work, or contact with a human 
TB patient) were known. The current control measures in 
place to prevent animal-to-human spread seem to be effec-
tive; such spread occurs in a few isolated incidents and spo-
radic events. However, to increase understanding of M. bo-
vis transmission in England, Wales, and Northern Ireland, 
we recommend strengthening collaboration between animal 
and human health, including linking genotyping results.
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